Winnipeg residents prefer Premier Wab Kinew’s New Democrats to PCs plan for health care by 2-1 - CUPE

Nfld. & LabradorNeither Newfoundland and Labrador Health Services nor the provincial health department are able to say when a new urgent care centre built in Mount Pearl will be able to open. Topsail Road centre is partially occupied, but staffing problems prevent NLHS from offering urgent carePatrick Butler · Radio-Canada · Posted: Oct 15, 2026 12:23 PM EDT | Last Updated: October 15Listen to this articleEstimated 3 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. The new building at 850 Topsail Road in Mount Pearl where Newfoundland and Labrador Health Services hopes to open the metro region's second urgent care clinic, seen here on Oct 13, 2026. (Patrick Butler/Radio-Canada)The Progressive Conservative government is holding fast to a promise to build a third urgent care centre in Conception Bay South, despite not being able to open a facility built more than a year ago in Mount Pearl. Infrastructure Minister Barry Petten, who is also the MHA for Conception Bay South, said Wednesday he intends for construction on the C. B. S.

OpinionThe Manitoba Premier is misinforming the public on Indian Residential Schools. Reverend Thompson Ferrier of Brandon Indian Residential School transporting indigenous students from Berens River to Brandon in 1904. Image courtesy of Manitoba MuseumPublished on:19 Oct 2026, 5:30 pmLoading content, please wait...

Patients with asthma and chronic obstructive pulmonary disease (COPD) often receive systemic corticosteroids from multiple specialties, and that cumulative exposure is rarely tracked in 1 place. At the same time, the options for reducing reliance on oral steroids have grown, with approvals of dupilumab and mepolizumab for eosinophilic COPD and of depemokimab, a twice-yearly anti-interleukin (IL)-5 agent, for severe asthma.1-4 Clinicians outside pulmonology increasingly manage these patients when specialty access is limited. On October 6, 2026, Mollie Chartoff, FNP-BC, a nurse practitioner on the advanced COPD team at Vanderbilt Lung Institute in Nashville, Tennessee, moderated a virtual clinical forum for advanced practice providers on asthma and COPD. Participants included nurse practitioners and physician assistants in pulmonology, allergy and asthma, dermatology, oncology, and interventional pain practices in Tennessee, Texas, Missouri, and North Carolina. The discussion covered biomarkers, oral corticosteroid (OCS) exposure, biologic selection, and access barriers.

Treatment of pulmonary arterial hypertension (PAH) now spans 5 therapeutic pathways, and the options within them continue to expand. Recent developments include FDA approval of a once-daily single-tablet combination of macitentan and tadalafil, supported by the phase 3 A DUE trial, and a September 2026 European Respiratory Society (ERS) guideline update recommending add-on sotatercept for patients who remain at intermediate-low, intermediate-high, or high risk.1,2 How clinicians sequence oral, inhaled, parenteral, and injectable therapies in practice increasingly depends on risk assessment, payer requirements, and patient preference. In September 2026, Marc Simon, MD, MS, director of pulmonary vascular disease and the Pulmonary Hypertension Comprehensive Care Center at the University of California, San Francisco (UCSF), moderated a clinical forum in San Francisco. Participants included pulmonologists, advanced heart failure and critical care cardiologists, and a nurse practitioner from UCSF, Kaiser Permanente, and California Pacific Medical Center. The discussion covered initial combination therapy, risk reassessment, escalation beyond dual therapy, and long-term monitoring.